Market Capital
₹60,079 Cr.
P/E
48.26
Share Price
₹ 1777.45 2.65 (0.15%)
Quick View
₹ 1777.45 2.65 (0.15%)
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Company Timeline

Forensics
ROE
Asset Turnover is responsible for ROE increase over last 10 years
Other Income
Other Income is not affecting ratios of the company
Depreciation Effect
Company is depreciating a lower percentage of assets. This is contributing to an increase in Net Profit
Pledge
Promoters have not pledged a significant portion of their holding
Debt
Company should not have issues servicing its debt
Current vs Historic Valuation
Company is trading at a premium to 3yr historic valuations
Working Capital
Working Capital of the company seems to be under control
Revenue Recognition
Chances of aggressive revenue recognition - Operating profit of company is not getting converted to cash and recievables rising faster than sales
Capex vs ROCE
ROCE of the company has increased over the last three years
Share price
Share price has increased over last 10 years but more due to rerating
Contingent Liabilities
Company does not have significant contingent liabilities
Promoter Holding
Promoter has not sold any shares in the last 90 days
Retail Holding
Retail has been selling the stock which is usually a good time to buy
ROE
Latest
13.06%
3yr Average
18.58%
5yr Average
15.93%
Net Profit Margin
Latest
9.13%
3yr Average
12.56%
5yr Average
10.95%
ROCE
Latest
24.0%
3yr Average
21.87%
5yr Average
19.26%
Debt to Equity
Latest
0.67
3yr Average
0.9
5yr Average
1.08
Market Share
3.16% (as of Jul 22)
Anti - Diabetes - Market Share
0.84% (as of Jul 22)
Anti-Infectives - Market Share
0.74% (as of Nov 21)
Anti-Malarial - Market Share
0.27% (as of Nov 21)
Antineo Plastic - Market Share
0.26% (as of Nov 21)
Blood Related - Market Share
7.22% (as of Jul 22)
Cardiovascular - Market Share
1.22% (as of Nov 21)
Dermatology - Market Share
0.01% (as of May 21)
Endocrinology - Market Share
4.93% (as of Jul 22)
Gastro-Intestinal - Market Share
1.50% (as of Nov 21)
Gynecology - Market Share
20% (as of Mar 19)
Losartan & Lamtrigine - Market Share in Brazil
7.53% (as of Nov 21)
Neurological - Market Share
0.01% (as of Mar 18)
Ophthalmology - Market Share
3.05% (as of Nov 21)
Pain - Market Share
3.40% (as of Dec 22)
Pharmaceutical Sector - Market Share
0.19% (as of Nov 21)
Respiratory - Market Share
0% (as of Jul 22)
Sex Stimulants - Market Share
30% (as of Mar 19)
Shelcal - Market Share
34.62% (as of May 19)
Stomatological - Market Share
0.40% (as of Nov 21)
Urology - Market Share
4.78% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Break-Up

locked
Source
|
Latest
|
locked
Historic

Acute vs Chronic

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • Number of ANDA's Filed in USA (Nos)
    • Number of ANDA's Approved By USFDA (Nos)
    • Domestic Sales Growth - YoY (%)
    • Management Compensation as a % of Sales (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Brands
    Losar
    Shelcal
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis